

Review of: "Sting Pathway Activation by Orally Administered Attenuated dsRNA Vaccine Virus for Therapy of Viral Diseases"

Marcelo Valdemir de Araujo¹

1 Universidade de São Paulo

Potential competing interests: No potential competing interests to declare.

Although the article provides good references on the use of IBDV, some information was missing to better clarify the treatment: for example, what the natural infection is like in birds, which cytokines the virus induces during poultry infection, and which transcription factors are stimulated?

Furthermore, some clarifications would be interesting to add. For example, how does IBDV stimulate STING? Furthermore, does it not stimulate any other receptors or transcription factors? What cytokines are produced during infection?

Regarding the treatment for CHB, what is the particular cytokine profile caused by the disease? During SIT, which cytokines are produced? Is there a change in the cytokine profile and immune pattern of the disease during treatment? What are the minimal effects?

Is the oral strategy used the best strategy? What is the difference in effectiveness between oral and intranasal strategies? Was any adjuvant used for SIT?

Qeios ID: OASKAH · https://doi.org/10.32388/OASKAH